Clinical Study of Neoadjuvant PD-1 Antibody (Toripalimab) Plus Chemotherapy for Locally Advanced Thymic Epithelial Tumor

Thymic Epithelial Tumor Clinical Trial

Official title:

Clinical Study of Neoadjuvant PD-1 Antibody (Toripalimab) Plus Chemotherapy for Locally Advanced Thymic Epithelial Tumor

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04667793
• Other study ID #: ChestMate-001(FK-NEO-TET-001)
• Status: Recruiting
• Phase: Phase 2
• Start date: January 31, 2021
• Est. completion date: April 30, 2024

Study information

• Verified date: April 2023
• Source: Shanghai Pulmonary Hospital, Shanghai, China
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase II, single-arm, open-label study to evaluate the efficacy and safety of neoadjuvant Toripalimab + chemotherapy followed by radical surgery as first-line treatment in patients with locally advanced thymic epithelial tumor.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 15
• Est. completion date: April 30, 2024
• Est. primary completion date: September 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Thymic epithelial tumor confirmed by needle biopsy;

• No systemic metastasis confirmed by PET-CT;

• Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 or 1.

• At stage III-IVA (masaoka-koga) as identified by chest CT or MRI;

• With the feasibility or anticipated feasibility after neoadjuvant therapy to receive radical surgery;

• Aged 18-75 years;

• At least 1 measurable lesion according to RECIST 1.1;

• Patients with good function of other main organs (liver, kidney, blood system, etc.):

• ANC count =1.5×10^9/L, platelet count =100×10^9/L,hemoglobin =90 g/L;

• the international standard ratio of prothrombin time (INR) and prothrombin time (PT) < 1.5 times of upper limit of normal (ULN);

• partial thromboplastin time (APTT) =1.5×ULN;

• total bilirubin =1.5×ULN;

• alanine aminotransferase (ALT) aspartate aminotransferase (AST) =2.5×ULN, or ALT and AST =5×ULN in the patients with liver metastatic tumor.

• The child-bearing female must undergo pregnancy test within 7 days before starting the treatment and the result shall be negative. Reliable contraceptive measures, such as intrauterine device, contraceptive pill and condom, shall be adopted during the trial and within 30 days after completion of the trial. The child-bearing male shall use condom for contraception during the trial and within 30 days after completion of the trial;

• The patient shall sign the Informed Consent Form.

Exclusion Criteria:

• Participants who have received any systemic anti-cancer treatment for thymic epithelial tumor, including surgical treatment, local radiotherapy, cytotoxic drug treatment, targeted drug treatment and experimental treatment;

• Administration of any Chinese medicine against cancer before administration of the drug;

• Participants with other cancer (excluding cervical carcinoma in situ, cured basal cell carcinoma, bladder epithelial tumor [including TA and tis]) within five years before the start of this study;

• Participants with any unstable systemic disease (including active infection, uncontrolled hypertension), unstable angina pectoris, angina pectoris starting in the last three months, congestive heart failure (>= NYHA) Grade II), myocardial infarction (6 months before admission), severe arrhythmia requiring drug treatment, liver, kidney or metabolic diseases;

• With activate or suspectable autoimmune disease, or autoimmune paracancer syndrome requiring systemic treatment;

• Antibiotics were used to treat the infection for 4 weeks prior to the start of the trial;

• Participants who were systemically treated with corticosteroids (prednisone or other corticosteroids >10 mg/ day) or other immunosuppressive agents within 2 weeks prior to first administration. In the absence of active autoimmune disease, inhaled or topical corticosteroids and adrenal hormone replacement therapy with a dose of less than 10 mg/ day of prednisone are permitted;

• Participants who are allergic to the test drug or any auxiliary materials;

• Participants with active hepatitis B, hepatitis C or HIV;

• The vaccine was administered within 4 weeks of the start of the trial;

• Participants who have undergone major surgery or severe trauma in other systems within 2 months before the start of this trial;

• Pleural effusion, pericardial effusion or ascites that are not clinically controlled and require pleural puncture or abdominal puncture drainage within 2 weeks before inclusion;

• The patients have active pia meningioma, uncontrolled or untreated brain metastases;

• Pregnant or lactating women;

• Participants suffering from nervous system diseases or mental diseases that cannot cooperate;

• Participated in another therapeutic clinical study;

• Other factors that researchers think it is not suitable for enrollment.

Related Conditions & MeSH terms

• Neoplasms, Glandular and Epithelial
• Thymic Epithelial Tumor
• Thymus Neoplasms

Intervention

Drug:
• Toripalimab + Chemotherapy
Toripalimab: 200mg, q3w, i.v., 2-4 cycles Chemotherapy: Thymoma: Cisplatin+Amycin+Cyclophosphamide Thymic carcinoma: Carboplatin+Paclitaxel

Locations

Country	Name	City	State
China	Shanghai Pulmonary Hospital	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Pulmonary Hospital, Shanghai, China

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety: frequency of severe adverse events	The frequency of severe adverse events from the participants enrolling to 30 days after the last drug administration or 30 days after surgery or new anti-cancer therapy, which comes first.	up to 5 months
Primary	Major pathologic response (MPR)	MPR is defined as the proportion of participants who have achieved major pathologic response (on routine hematoxylin and eosin staining, tumors with no more than 10% viable tumor cells) in all participants who have completed the neoadjuvant therapy before surgery.	up to 4 months
Secondary	Objective response rate (ORR)	It refers to the proportion of patients who have had a complete response or partial response (according to RECIST1.1) as confirmed by CT evaluation after 3 weeks in all patients who have completed the neoadjuvant therapy. Only patients with measurable lesions at baseline will be analyzed.	up to 4 months
Secondary	Disease-free survival (DFS)	It refers to the time from radical surgery to relapse or death of a participant due to disease progression. In the case of a patient who still survives at the time of analysis, the latest evaluation date will be used for interpolation (censoring).	up to 60 months
Secondary	Overall survival (OS)	It is defined as the time from enrollment to death of participant due to any cause. In the case of a patient who still survives at the time of analysis, the date of last contact will be taken as the censoring date. In the event of a patient with the survival status unknown, the date when the patient is last known to be alive will be used for interpolation (censoring).	up to 60 months
Secondary	Health related quality of life (HRQol)	The assessment is made according to the Quality of Life Scale for Lung Cancer Patients (EORTC-QLQ-C30 & LC13, Version 3). EORTC's QLQ-C30 & LC13 (V3.0) is a core scale for lung cancer patients, with a total of 43 items. Among them, Item 29 and 30 are divided into seven grades, which are assigned with 1 to 7 scores according to the answer options. The other items are divided into 4 grades: Not at All, A Little, Quite a Bit, and Very Much, assigned with 1 to 4 scores respectively. The higher score, the worse quality.	up to 6 months